Genetic Investigation of Covid 19 in Lung Disease
Genetic Investigation of Covid 19 in Lung Disease
批准号:
10768221
负责人:
MARK L KAHN
金额:
$16.89万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2027-07-31
关键词:
2019-nCoVACE2AcuteAcute Respiratory Distress SyndromeAddressAllelesBloodBlood VesselsBreedingCOVID-19COVID-19 testCase SeriesCell LineageCellsClinicalCoagulation ProcessDefectDiseaseEndotheliumEpithelial CellsEquipmentEtiologyExhibitsF2R geneGenerationsGeneticGenetic ModelsGenomicsHistologicHumanHypoxiaInfectionInflammatoryInfluenzaInvestigationKidneyKnowledgeLaboratoriesLearningLiverLungLung diseasesMediatingMusOrganOxygenPathogenicityPathologyPatientsPhenotypeProductionPulmonary PathologyReagentReporterResourcesRespiratory distressSARS-CoV-2 infectionSeveritiesSourceSpecimenSurveysTechniquesThrombinThrombosisThrombusTimeTissuesWorkbetacoronaviruscytokinedefined contributiongenetic approachinterestlung injurymouse geneticsmouse modelnonhuman primateparent grantpost SARS-CoV-2 infectionthrombotictranscriptome sequencingvascular bedvascular contributionsvascular injury
中文摘要
项目摘要
由β-冠状病毒SARS-CoV-2引起的致命COVID-19疾病表现为
呼吸窘迫与血氧饱和度水平的快速下降,虽然其他
器官缺陷经常在患者和临床病例系列中描述。人类的描述性研究
患者提出了许多致病机制,包括直接
上皮细胞感染、血管细胞感染和血栓形成,并释放炎性细胞因子。
然而,这些假设仍然纯粹是相互关联的,因为因果关系不能严格建立在
人类病人小鼠遗传方法尚未用于测试COVID-19
致病机制为了解决这一知识缺口,我们建立了新的小鼠遗传模型,
其表达来自小鼠Ace 2基因座的hACE 2,其水平足以引起致死性疾病,缺氧,
和肺血管血栓形成,如在人类患者中观察到的。
最初的资助计划是研究这些现象的血管机制,
包括1.2)确定急性ARDS表型或
SARS-CoV 2感染引起的长期肺损伤; 1.3)确定血管细胞感染的贡献
急性ARDS表型或SARS-CoV 2感染引起的长期肺损伤;以及3)比较
并对比流感与SARS-CoV-2对肺血管和血栓形成的影响。
随后,我们探讨了COVID-19对肺血管内
使用与我们的hACE 2小鼠繁殖的PAR 1-Tango报告基因等位基因进行血栓形成,并观察到
多个器官(肺、肾、肝)血管床中PAR 1-Tango活性异常,
SARS-CoV-2感染,这是意料之外的,因为明显的血栓仅存在于肺部。
除了这些新的发现,我们还了解到使用Cre/lox介导的内皮细胞缺失,
hACE 2,SARS-CoV-2血管感染不太可能导致我们
观察本补充文件提出了额外的工作,以便:a)揭示的程度和严重性,
COVID-19疾病中的血管损伤,使用PAR 1-Tango标本; B)了解实际
利用广泛的多器官系统研究SARS-CoV-2感染中凝血酶产生的机制
免疫组织学检查;和c)使用
来自感兴趣的组织和/或区域的RNA测序。因为大多数标本已经
该补编已收集,但有待深入分析,非常适合扩大联合国的工作,
但在原有的范围内。不需要额外的设备或试剂来追踪
这些研究,而不是需要候选人的时间和精力以及资源
在Kahn实验室已经有了。
英文摘要
Project Summary
Lethal COVID-19 disease caused by the beta-coronavirus SARS-CoV-2 is manifest as
respiratory distress associated with a rapid decline in blood oxygen saturation levels, though other
organ defects are often described in patients and clinical case series. Descriptive studies of human
patients have proposed numerous pathogenic mechanisms for these findings, including direct
epithelial cell infection, vascular cell infection and thrombosis, and released inflammatory cytokines.
However, these hypotheses remain purely correlative as causality cannot be rigorously established in
human patients. Mouse genetic approaches have not yet been harnessed to test COVID-19
pathogenic mechanisms. To address this gap in knowledge we generated new mouse genetic models
that express hACE2 from the mouse Ace2 locus at levels sufficient to confer lethal disease, hypoxia,
and pulmonary vascular thrombosis like that observed in human patients.
The parent grant initially proposed to work on vascular mechanisms of these phenomenon,
including to 1.2) Determine the epithelial cell lineages necessary for either acute ARDS phenotype or
long term lung damage by SARS-CoV2 infection; 1.3) Define the contribution of vascular cell infection
for either acute ARDS phenotype or long term lung damage by SARS-CoV2 infection; and 3) Compare
and contrast the lung vascular and thrombotic effects of influenza versus SARS-CoV-2.
Subsequently, we have explored the mechanism of COVID-19 on pulmonary intravascular
thrombosis using the PAR1-Tango reporter allele bred with our hACE2 mice, and have observed
abnormal PAR1-Tango activity in the vascular beds of multiple organs (lung, kidney, liver) following
SARS-CoV-2 infection, which is unexpected since obvious thrombi are only present in the lungs.
Besides these new findings, we have also learned using Cre/lox-mediated endothelial deletion of
hACE2, that vascular infection by SARS-CoV-2 is not likely responsible for any major phenotypes we
observed. This supplement proposes additional work in order to: a) reveal the extent and severity of
vascular injury in COVID-19 disease, using PAR1-Tango specimens; b) understand the actual
mechanisms of thrombin generation in SARS-CoV-2 infection by employing an extensive multi-organ
immunohistological survey; and c) confirm sources of pro-thrombotic or inflammatory factors using
RNA sequencing from the tissues and/or regions of interest. As the majority of specimens are already
collected, but awaiting in-depth analysis, the supplement is well-suited to extend the work of the
parent grant, but within its original scope. Additional equipment or reagents are not needed to pursue
these studies, which instead require the time and effort of the candidate together with resources
already available in the Kahn laboratory.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetic Investigation of Covid 19 in Lung Disease
-
批准号:10673004
-
项目类别:
-
资助金额:$90.87万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
-
批准号:10417684
-
项目类别:
-
资助金额:$59.82万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Genetic Investigation of Covid 19 in Lung Disease
-
批准号:10502908
-
项目类别:
-
资助金额:$92.28万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Reciprocal VEGFC/VEGFR3-CDH5 regulation of lymphatic and sinusoidal vascular growth
-
批准号:10608143
-
项目类别:
-
资助金额:$60.63万
-
财政年份:2022
-
负责人:MARK L KAHN
-
依托单位:
Molecular and genetic basis of deep venous thrombosis
-
批准号:10460687
-
项目类别:
-
资助金额:$35.88万
-
财政年份:2021
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10226236
-
项目类别:
-
资助金额:$72.28万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10626893
-
项目类别:
-
资助金额:$70.3万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10033435
-
项目类别:
-
资助金额:$72.58万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
Flow and endothelial signaling in acquired myxomatous valve disease
-
批准号:10408810
-
项目类别:
-
资助金额:$71.72万
-
财政年份:2020
-
负责人:MARK L KAHN
-
依托单位:
MEKK3 signaling in hemogenic endothelium
-
批准号:10198023
-
项目类别:
-
资助金额:$76.08万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
Molecular and genetic basis of deep venous thrombosis
-
批准号:10200879
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
Molecular and genetic basis of deep venous thrombosis
-
批准号:10225228
-
项目类别:
-
资助金额:$42.03万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
MEKK3 signaling in hemogenic endothelium
-
批准号:9765393
-
项目类别:
-
资助金额:$80.72万
-
财政年份:2018
-
负责人:MARK L KAHN
-
依托单位:
TLR4 and the microbiome in CCM disease
-
批准号:9912850
-
项目类别:
-
资助金额:$56.57万
-
财政年份:2017
-
负责人:MARK L KAHN
-
依托单位:
TLR4 and the microbiome in CCM disease
-
批准号:10152688
-
项目类别:
-
资助金额:$53.96万
-
财政年份:2017
-
负责人:MARK L KAHN
-
依托单位:
TLR4 and the microbiome in CCM disease
-
批准号:9287514
-
项目类别:
-
资助金额:$60.08万
-
财政年份:2017
-
负责人:MARK L KAHN
-
依托单位:
Downstream molecular mechanisms underlying cerebral cavernous malformation
-
批准号:10220147
-
项目类别:
-
资助金额:$31.47万
-
财政年份:2015
-
负责人:MARK L KAHN
-
依托单位:
Downstream molecular mechanisms underlying cerebral cavernous malformation
-
批准号:10417156
-
项目类别:
-
资助金额:$31.18万
-
财政年份:2015
-
负责人:MARK L KAHN
-
依托单位:
Downstream molecular mechanisms underlying cerebral cavernous malformation
-
批准号:10621255
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2015
-
负责人:MARK L KAHN
-
依托单位:
Genetic Investigation of pulmonary lymphatic development and function
-
批准号:8761251
-
项目类别:
-
资助金额:$41.57万
-
财政年份:2014
-
负责人:MARK L KAHN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
-
批准号:82570085
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:沈慧
-
依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
-
批准号:82404910
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:郝单丽
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ACE2通过AMPK/SIRT3调控线粒体代谢改善盐敏感性高血压肾脏纤维化的机制
-
批准号:82460087
-
项目类别:地区科学基金项目
-
资助金额:33.00万元
-
批准年份:2024
-
负责人:赵宇
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位: